Krystal Biotech Inc. (KRYS)

Krystal Biotech tops Q2 estimates with strong Vyjuvek sales, but shares fall 14% on weak Q3 revenue guidance.

Krystal Biotech, Inc. (NASDAQ:KRYS ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Kathryn A. Romano - Executive VP & Chief Accounting Officer Krish S.

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $0.86 per share a year ago.

Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.

Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.

Krystal Biotech rises 4% after dosing begins in a phase III study of KB803 eye drops to treat rare DEB-related corneal damage.

Krystal Biotech (KRYS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near t...

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?